AB Science

AB Science is a renowned French pharmaceutical company that specializes in the research and development of innovative therapies for the treatment of severe diseases. The company's primary focus is on developing targeted therapies for diseases with high unmet medical needs, such as cancer, inflammatory diseases, and neurodegenerative disorders. AB Science's approach is based on a deep understanding of the underlying biology of these diseases, which allows them to develop therapies that target specific pathways and mechanisms. The company's lead product candidate, masitinib, is a tyrosine kinase inhibitor that has shown promising results in clinical trials for the treatment of various cancers, including gastrointestinal stromal tumors and pancreatic cancer. AB Science is committed to improving the lives of patients with severe diseases by developing innovative therapies that address their unmet medical needs.